Prague Med. Rep. 2023, 124, 40-51
https://doi.org/10.14712/23362936.2023.4
A Critical Analysis of the Magnetic Resonance Imaging Lesion Diameter Threshold for Adverse Pathology Features
References
1. , C., Becker, N., Rabenalt, R., Hiester, A., Quentin, M., Dietzel, F., Antoch, G., Gabbert, H. E., Albers, P., Schimmöller, L. (2015) The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J. Cancer Res. Clin. Oncol. 141(11), 2061–2068.
<https://doi.org/10.1007/s00432-015-1991-5>
2. , T. J., Hayward, R. A., Reamer, E., Zikmund-Fisher, B. J., Connochie, D., Heisler, M., Fagerlin, A. (2016) Presentation of benefits and harms in US cancer screening and prevention guidelines: systematic review. J. Natl. Cancer Inst. 108(6), djv436.
<https://doi.org/10.1093/jnci/djv436>
3. , T., Chen, M.-H., Renshaw, A. A., Loffredo, M., Richie, J. P., D’Amico, A. V. (2005) Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology 66(5), 1024–1028.
<https://doi.org/10.1016/j.urology.2005.05.037>
4. , F. F., Felker, E. R., Kwan, L., Sisk, A. E., Delfin, M., Natarajan, S., Marks, L. S. (2019) Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: The prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study. JAMA Surg. 154(9), 811–818.
<https://doi.org/10.1001/jamasurg.2019.1734>
5. , J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., Humphrey, P. A. (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 40(2), 244–252.
<https://doi.org/10.1097/PAS.0000000000000530>
6. , E. R., Margolis, D. J., Nassiri, N., Marks, L. S. (2016) Prostate cancer risk stratification with magnetic resonance imaging. Urol. Oncol. 34(7), 311–319.
<https://doi.org/10.1016/j.urolonc.2016.03.001>
7. , S. J., Kane, C. J., Amling, C. L., Aronson, W. J., Terris, M. K., Presti, J. C. Jr. (2007) Upgrading and downgrading of prostate needle biopsy specimens: Risk factors and clinical implications. Urology 69(3), 495–499.
<https://doi.org/10.1016/j.urology.2006.10.036>
8. , R. A., Holmberg, E., Lilja, H., Stranne, J., Hugosson, J. (2015) Opportunistic testing versus organized prostate-specific antigen screening: Outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur. Urol. 68(3), 354–360.
<https://doi.org/10.1016/j.eururo.2014.12.006>
9. , R., Siddiqui, M. M., George, A. K., Frye, T., Kilchevsky, A., Fascelli, M., Shakir, N. A., Chelluri, R., Abboud, S. F., Walton-Diaz, A., Sankineni, S., Merino, M. J., Turkbey, B., Choyke, P. L., Wood, B. J., Pinto, P. A. (2016) Preoperative multiparametric magnetic resonance imaging predicts biochemical recurrence in prostate cancer after radical prostatectomy. PLoS One 11(6), e0157313.
<https://doi.org/10.1371/journal.pone.0157313>
10. , M. W., Stapleton, A. M., Wheeler, T. M., Scardino, P. T. (1997) Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79(3), 528–537.
<https://doi.org/10.1002/(SICI)1097-0142(19970201)79:3<528::AID-CNCR15>3.0.CO;2-5>
11. , C., Roudot-Thoraval, F., Moktefi, A., Bouanane, M., De La Taille, A., Salomon, L. (2017) Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy. World J. Urol. 35(9), 1409–1415.
<https://doi.org/10.1007/s00345-016-1981-5>
12. , D. H., Koo, K. C., Lee, S. H., Rha, K. H., Choi, Y. D., Hong, S. J., Chung, B. H. (2013) Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: Preliminary analysis. J. Urol. 190(4), 1213–1217.
<https://doi.org/10.1016/j.juro.2013.03.127>
13. , A., Sharma, V., Viers, B. R., Rangel, L. J., Carlson, R. E., Froemming, A. T., Karnes, R. J. (2017) The incremental role of magnetic resonance imaging for prostate cancer staging before radical prostatectomy. Eur. Urol. 71(5), 701–704.
<https://doi.org/10.1016/j.eururo.2016.08.015>
14. Mottet, N., van den Bergh, R., Briers, E. (2019) EAU Guidelines Edn. presented at the EAU Annual Congress Barcelona.
15. , N., Chang, E., Lieu, P., Priester, A. M., Margolis, D. J., Huang, J., Reiter, R. E., Dorey, F. J., Marks, L. S., Natarajan, S. (2018) Focal therapy eligibility determined by magnetic resonance imaging/ultrasound fusion biopsy. J. Urol. 199(2), 453–458.
<https://doi.org/10.1016/j.juro.2017.08.085>
16. , E., Akpınar, Ç., İbiş, A., Kubilay, E., Erden, A., Yaman, Ö. (2021) Effect of lesion diameter and prostate volume on prostate cancer detection rate of magnetic resonance imaging: Transrectal-ultrasonography-guided fusion biopsies using cognitive targeting. Turk. J. Urol. 47(1), 22.
<https://doi.org/10.5152/tud.2020.20238>
17. , A. B., Babb, J. S., Taneja, S. S., Ream, J. M. (2017) Proposed adjustments to PI-RADS version 2 decision rules: Impact on prostate cancer detection. Radiology 283(1), 119–129.
<https://doi.org/10.1148/radiol.2016161124>
18. , M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., Wei, J. T. (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250–1261.
<https://doi.org/10.1056/NEJMoa074311>
19. , F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., Denis, L. J., Recker, F., Paez, A., Bangma, C. H., Carlsson, S., Puliti, D., Villers, A., Rebillard, X., Hakama, M., Stenman, U. H., Kujala, P., Taari, K., Aus, G., Huber, A., van der Kwast, T. H., van Schaik, R. H., de Koning, H. J., Moss, S. M., Auvinen, A. (2014) Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959), 2027–2035.
<https://doi.org/10.1016/S0140-6736(14)60525-0>
20. , D. M., Sauvageot, J., Piantadosi, S., Epstein, J. I. (1997) Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am. J. Surg. Pathol. 21(5), 566–576.
<https://doi.org/10.1097/00000478-199705000-00010>
21. Toledano, A. Y., Obuchowski, N. A. (2016) Methods for quantitative imaging biomarker studies. In: Handbook for Clinical Trials of Imaging and Image-guided Interventions. Obuchowski, N. A., Scott Gazelle, G., pp. 170–188, Wiley Blackwell, Hoboken.
22. , P. P., Kuisma, M., Pääkkö, E., Hirvikoski, P., Vaarala, M. H. (2018) Lesion size on prostate magnetic resonance imaging predicts adverse radical prostatectomy pathology. Scand. J. Urol. 52(2), 111–115.
<https://doi.org/10.1080/21681805.2017.1414872>
23. , B., Mani, H., Shah, V., Rastinehad, A. R., Bernardo, M., Pohida, T., Pang, Y., Daar, D., Benjamin, C., McKinney, Y. L., Trivedi, H., Chua, C., Bratslavsky, G., Shih, J. H., Linehan, W. M., Merino, M. J., Choyke, P. L., Pinto, P. A. (2011) Multiparametric 3T prostate magnetic resonance imaging to detect cancer: Histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J. Urol. 186(5), 1818–1824.
<https://doi.org/10.1016/j.juro.2011.07.013>
24. , J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., Thoeny, H. C., Verma, S. (2016) PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. Eur. Urol. 69(1), 16–40.
<https://doi.org/10.1016/j.eururo.2015.08.052>


